ArticleExperimental and therapeutic medicine2012
Modulation of estrogenic action in clear cell carcinoma of the ovary (Review).
Article in Experimental and therapeutic medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Primary Carcinomas of the Episiotomy Scar Site: A Systematic Literature Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- New insights about endometriosis-associated ovarian cancer: pathogenesis, risk factors, prediction and diagnosis and treatment.Frontiers in oncology · 2024Review
- Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer.BMC cancer · 2023Article
- Endometriosis in clear cell and endometrioid carcinoma ovary: its impact on clinicopathological characteristics and survival outcomes.Ecancermedicalscience · 2023Article
- Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study.Journal of ovarian research · 2021Article
- Endometriosis-associated Ovarian Clear Cell Carcinoma: A Special Entity?Journal of Cancer · 2021Review
- Endometriosis and ovarian cancer: Their association and relationship.European journal of obstetrics & gynecology and reproductive biology: X · 2019Article
- Circulating miRNAs as Biomarkers for Endometriosis and Endometriosis-Related Ovarian Cancer-An Overview.Journal of clinical medicine · 2019Review
- Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.Yonsei medical journal · 2017Article
- Developmental Toxicant Exposure Is Associated with Transgenerational Adenomyosis in a Murine Model.Biology of reproduction · 2016Article
- Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.PloS one · 2016Article
- Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary.Oncology letters · 2015Article
- Endometriosis: pathogenesis and treatment.Nature reviews. Endocrinology · 2014Review
- Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review).Oncology letters · 2013Article
- Endometriosis-associated ovarian cancer: a review of pathogenesis.International journal of molecular sciences · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two histologic types, clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC), are the common histology in ovarian cancer patients who have associated endometriosis. However, both tumor types have distinct clinicopathological characteristics and molecular phenotypes. EAC is predominantly positive for estrogen receptor (ER), but CCC specifically exhibits lower ER expression. This study reviews the current understanding of the role of the ER information in the pathogenesis of CCC, as well as the English language literature for biochemical studies on ER expression and estrogenic action in CCC. The iron-mediated oxidative stress occurs due to repeated hemorrhage in endometriosis, then this compound oxidatively modifies genomic DNA and, subsequently, ER depletion may be observed. There are a number of factors that interfere with ER expression and estrogen activity, which include DNA methylation of the promoter region, histone deacetylation, heme and iron binding, chromatin remodeling and ubiquitin ligase activity. Loss of estrogen function may be a turning point in CCC progression and aggressiveness.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.